Ultragenyx Pharmaceutical Inc
Held by 8 tracked managers as of Q2 2026 · CUSIP ⓘCUSIP: A 9-character ID for one specific security - one share class of one company, or one bond. Tickers can change and can mean different things in different countries; a CUSIP always identifies exactly the same security, which is why filings use it. Guide 90400D108 · Sector ⓘGICS sectors: The 11-sector system most investors know (Global Industry Classification Standard): Technology, Health Care, Financials and so on. This site assigns each company a GICS-style sector from its SIC code, with a few hand corrections, so sector pages match the names investors expect. Guide
Educational and informational only, not personalized investment advice. Based on public filings that may be delayed or contain errors; verify with the original filings. Disclaimer
Tracked capital in this stock
Total value held (area) and number of managers (line). Dips can mean a large holder filed that quarter confidentially (e.g. Norges Bank in Q1/Q3).
Aggregate buying and selling
Net share change reported each quarter
Who owns RARE?
🔒 The 'who added and who trimmed' chart is a Plus feature
You're viewing the Free plan. Upgrade to unlock The 'who added and who trimmed' chart — every paid plan starts with a 7-day free trial, and you can cancel in two clicks.
Who owns RARE? — Q2 2026
Holders ranked by position size, with each one's quarter-over-quarter change.
Column filters
| # | Manager | Fund | Shares | Value ↓ | % of their portfolio | QoQ | Δ shares | Δ shares % | Est. Δ value ⓘChange in shares × this quarter's price |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Two Sigma | Two Sigma Investments | 3.62M | $120.91M | 0.1% | Added | +1.4M | +64.2% | +$47.26M |
| 2 | Sands Capital | Sands Capital Management | 3.16M | $105.46M | 0.4% | Reduced | -56.2K | -1.7% | -$1.88M |
| 3 | David Shaw | D.E. Shaw & Co. | 1.73M | $57.77M | 0.0% | Added | +469.2K | +37.2% | +$15.67M |
| 4 | Israel Englander | Millennium Management | 760.83K | $25.40M | 0.0% | Reduced | -1.0M | -57.1% | -$33.77M |
| 5 | Jim Simons | Renaissance Technologies | 413.70K | $13.81M | 0.0% | Reduced | -148.0K | -26.3% | -$4.94M |
| 6 | Ken Griffin | Citadel Advisors | 210.53K | $7.03M | 0.0% | Reduced | -1.9M | -90.0% | -$63.61M |
| 7 | Fred Alger | Fred Alger Management | 143.16K | $4.78M | 0.0% | Reduced | -154.9K | -52.0% | -$5.17M |
| 8 | Norges Bank | Norges Bank Investment Management | 78.49K | $2.62M | 0.0% | — | — | — | — |
Column filters
| Manager | Fund | Shares sold | Value last quarter ↓ |
|---|---|---|---|
| Steve Cohen | Point72 Asset Management | -893.3K | $18.71M |
Politician trades
Column filters
| Politician | Date | Ticker | Asset | Type | Reported range ⓘThe dollar range the politician reported. Exact amounts are not disclosed. | Est. size ⓘOur estimate only: the midpoint of the reported range. | Owner | Account ⓘSubholding Of: the account the trade was in, as named on the report (e.g. an IRA or a brokerage account). The same stock bought on the same day in different accounts is a separate trade in each account. | Filed ↓ | Filing delay ⓘDays between the trade and the report. Over 45 days is late under the STOCK Act. | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gil Cisneros Politician | Sep 29, 2026 | RARE | Ultragenyx Pharmaceutical Inc. - Common Stock (RARE) [ST] | Purchase | $1,001 - $15,000 | Est. $8,000 (midpoint of reported range $1,001–$15,000) | Self | 150 Main Street Trust > Bank of America | Oct 12, 2026 | 13 days | PTR ↗ |
| Gil Cisneros Politician | Mar 3, 2026 | RARE | Ultragenyx Pharmaceutical Inc. - Common Stock (RARE) [ST] | Purchase | $1,001 - $15,000 | Est. $8,000 (midpoint of reported range $1,001–$15,000) | Self | 150 Main Street Trust > Bank of America | Apr 7, 2026 | 35 days | PTR ↗ |
| Gil Cisneros Politician | Feb 18, 2026 | RARE | Ultragenyx Pharmaceutical Inc. - Common Stock (RARE) [ST] | Purchase | $1,001 - $15,000 | Est. $8,000 (midpoint of reported range $1,001–$15,000) | Self | 150 Main Street Trust > Bank of America | Mar 9, 2026 | 19 days | PTR ↗ |
| Gil Cisneros Politician | Aug 8, 2025 | RARE | Ultragenyx Pharmaceutical Inc. - Common Stock (RARE) [ST] | Purchase | $1,001 - $15,000 | Est. $8,000 (midpoint of reported range $1,001–$15,000) | Self | 150 Main Street Trust > Bank of America | Sep 12, 2025 | 35 days | PTR ↗ |
| Gil Cisneros Politician | Jul 15, 2025 | RARE | Ultragenyx Pharmaceutical Inc. - Common Stock (RARE) [ST] | Purchase | $1,001 - $15,000 | Est. $8,000 (midpoint of reported range $1,001–$15,000) | Self | — | Aug 14, 2025 | 30 days | PTR ↗ |